It has been reported that the ginsenosides Rg1 and Rf improve memory loss and cognitive dysfunction by regulating NF-κB, NLRP1, TLR3, and TLR4 signaling pathways, or interferon-gamma (IFN-γ) and active caspase-1 in an Alzheimer’s disease model (Du et al. 2018; Wu et al. 2022). This evidence concerns the gene IFNG and early-onset autosomal dominant Alzheimer disease.